Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Gross Profit history
Currency unavailable · from the income statement
No Gross Profit data reported for this period type.
Gross Profit vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $201.36M USD | +7.0% | -4.1% | 92.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $19M USD | +2140.8% | — | 95.0% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$79K USD | — | — | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$82K USD | — | — | — |
| LTM Mar 2026 | -$268K USD | — | — | — | |
| LTM Mar 2026 | -$574K USD | -69.3% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$5.01M USD | — | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +7.0% | -4.1% | 93.7% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.